What is Figure 1?
Founded in 2013, Figure 1 operates a specialized mobile-first network designed to facilitate the secure sharing and viewing of medical cases among healthcare professionals. By bridging the gap between clinical practice and digital collaboration, the platform serves as a vital resource for medical education, diagnostic support, and peer-to-peer knowledge exchange. Its market position is defined by its ability to aggregate high-value clinical data while maintaining strict adherence to privacy standards, making it an indispensable tool for practitioners navigating complex medical scenarios.
How much funding has Figure 1 raised?
Figure 1 has raised a total of $19.5M across 4 funding rounds:
Angel/Seed
$2M
Private Equity
$2.5M
Series A
$5M
Series B
$10M
Angel/Seed (2013): $2M with participation from Investment Accelerator Fund, Rho Canada Ventures, VersionOne, and Ryerson Futures Inc.
Private Equity (2015): $2.5M, investors not publicly disclosed
Series A (2015): $5M supported by Rho Canada Ventures, Union Square Ventures, VersionOne, and Allen & Company
Series B (2017): $10M featuring Hedgewood, John Hancock, Western Technology Investment, VersionOne, Union Square Ventures, Kensington Capital Partners, Rho Canada Ventures, and Samsung NEXT
Key Investors in Figure 1
Rho Canada Ventures
A venture capital firm with a long history of investing in innovation since 1981, focusing on companies at various stages of growth and providing strategic value through extensive operational experience.
Union Square Ventures
A New York City-based venture capital firm that targets transformative markets influenced by technological and societal shifts, partnering with visionary entrepreneurs to build the future.
VersionOne
An early-stage venture fund dedicated to supporting mission-driven founders in emerging markets, often engaging with companies before their market categories are fully defined.
What's next for Figure 1?
With the support of its latest financing, Figure 1 is well-positioned to deepen its penetration into international markets and enhance its suite of collaborative tools. The strategic focus will likely shift toward leveraging its vast repository of clinical insights to drive further innovation in medical diagnostics and professional development. As the company moves beyond its Series B stage, the emphasis will remain on scaling its user base and integrating advanced analytical capabilities to maintain its competitive edge in the rapidly evolving health-tech sector.
See full Figure 1 company page
